©The Author(s) 2025.
World J Gastrointest Oncol. Nov 15, 2025; 17(11): 111250
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.111250
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.111250
Table 1 Baseline demographic and clinicopathological characteristics of patients treated with rectal cancer and preoperative induction therapy followed by dedicated operation vs standard long course chemoradiotherapy, mean ± SD/n (%)
| Characteristic | TNT-RAPIDO (n = 29) | LCCRT (n = 70) | P value |
| Age (years) | 58.2 ± 1.9a | 64.7 ± 1.3a | 0.007 |
| Gender | 0.786 | ||
| Male | 24 (82.8) | 55 (78.6) | |
| Female | 5 (17.2) | 15 (21.4) | |
| BMI | 23.8 ± 0.8 | 23.1 ± 0.5 | 0.415 |
| ECOG performance status | 0.309 | ||
| 0 | 16 (55.2) | 30 (42.9) | |
| 1 | 13 (44.8) | 33 (47.1) | |
| 2 | 0 | 7 (10.0) | |
| MRI T stage | 0.082 | ||
| 1 | 0 | 0 | |
| 2 | 1 (3.4) | 4 (5.7) | |
| 3 | 20 (69.0) | 59 (84.3) | |
| 4 | 8 (27.6) | 7 (10.0) | |
| MRI N stage | 0.638 | ||
| 0 | 2 (6.9) | 8 (11.4) | |
| 1 | 15 (51.7) | 39 (55.7) | |
| 2 | 12 (41.4) | 23 (32.9) | |
| EMVI | 0.660 | ||
| Positive | 16 (55.2) | 34 (48.6) | |
| Negative | 13 (44.8) | 36 (51.4) | |
| CRM | 0.235 | ||
| Positive | 18 (62.1) | 52 (74.3) | |
| Negative | 11 (37.9) | 18 (25.7) | |
| PSW | 0.597 | ||
| Positive | 5 (17.2) | 17 (24.3) | |
| Negative | 24 (82.8) | 53 (75.7) | |
| Interval to surgery [weeks; median (interquartile range)] | 29.9 (24.0-33.7)a | 19.0 (16.1-21.3)a | < 0.001 |
| Mode of surgery | 0.089 | ||
| Open | 0 | 4 (5.7) | |
| Laparoscopic | 10 (34.5) | 36 (51.4) | |
| Robotic | 19 (65.5) | 30 (42.9) |
- Citation: Jabbar SAA, Choo ALE, Wong NW, Ngu JCY, Teo NZ. Comparing early surgical outcomes between total neoadjuvant therapy and standard long course chemoradiotherapy for rectal cancer. World J Gastrointest Oncol 2025; 17(11): 111250
- URL: https://www.wjgnet.com/1948-5204/full/v17/i11/111250.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i11.111250